These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9048487)

  • 21. [Melanocyte antibodies in idiopathic vitiligo (author's transl)].
    Höfs T; Zugehör M; Morenz J
    Dermatol Monatsschr; 1981 Nov; 167(11):685-92. PubMed ID: 7044847
    [No Abstract]   [Full Text] [Related]  

  • 22. The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.
    Teulings HE; Willemsen KJ; Glykofridis I; Krebbers G; Komen L; Kroon MW; Kemp EH; Wolkerstorfer A; van der Veen JP; Luiten RM; Tjin EP
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1086-96. PubMed ID: 25043574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitiligo and antibodies to melanocytes.
    Bystryn JC; Pfeffer S
    Prog Clin Biol Res; 1988; 256():195-206. PubMed ID: 3285350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Detection of antibodies to melanoma cells in vitiligo by 125I-labeled SpA antibody binding assay].
    Mori N; Shimada K; Satoh N; Nagao S; Iijima S; Kanzaki T
    Nihon Hifuka Gakkai Zasshi; 1986 Jul; 96(8):835-8. PubMed ID: 3784053
    [No Abstract]   [Full Text] [Related]  

  • 25. Vitiligo patients from India (Mumbai) show differences in clinical, demographic and autoantibody profiles compared to patients in western countries.
    Pradhan V; Patwardhan M; Thakkar V; Kharkar V; Khopkar U; Ghosh K; Weetman AP; Gawkrodger DJ; Kemp EH
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):279-86. PubMed ID: 22122088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Antibodies to Melanocytes in Patients With Vitiligo Are Predictors of Disease Progression.
    Jimenez-Brito G; Garza-de-La-Peña E; Pérez-Romano B; Ruiz-Argüelles A
    Skinmed; 2016; 14(1):17-21. PubMed ID: 27072723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
    Garbelli S; Mantovani S; Palermo B; Giachino C
    Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunodetection of the MCHR1 antibody in vitiligo patient sera.
    Zhou M; Guan C; Lin F; Xu W; Fu L; Hong W; Wan Y; Xu A
    Int J Mol Med; 2011 May; 27(5):725-9. PubMed ID: 21369690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo.
    al Badri AM; Foulis AK; Todd PM; Gariouch JJ; Gudgeon JE; Stewart DG; Gracie JA; Goudie RB
    J Pathol; 1993 Feb; 169(2):203-6. PubMed ID: 8095298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo.
    Kemp EH; Emhemad S; Akhtar S; Watson PF; Gawkrodger DJ; Weetman AP
    Exp Dermatol; 2011 Jan; 20(1):35-40. PubMed ID: 21158937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
    Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
    Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies to melanocytes. Occurrence in patients with vitiligo and chronic mucocutaneous candidiasis.
    Howanitz N; Nordlund JL; Lerner AB; Bystryn JC
    Arch Dermatol; 1981 Nov; 117(11):705-8. PubMed ID: 7316530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin.
    Le Poole IC; Stennett LS; Bonish BK; Dee L; Robinson JK; Hernandez C; Hann SK; Nickoloff BJ
    Br J Dermatol; 2003 Oct; 149(4):739-48. PubMed ID: 14616364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunopathogenesis of vitiligo.
    Sandoval-Cruz M; García-Carrasco M; Sánchez-Porras R; Mendoza-Pinto C; Jiménez-Hernández M; Munguía-Realpozo P; Ruiz-Argüelles A
    Autoimmun Rev; 2011 Oct; 10(12):762-5. PubMed ID: 21334464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of oxidative stress and autoimmunity in onset and progression of vitiligo.
    Laddha NC; Dwivedi M; Mansuri MS; Singh M; Gani AR; Yeola AP; Panchal VN; Khan F; Dave DJ; Patel A; Madhavan SE; Gupta R; Marfatia Z; Marfatia YS; Begum R
    Exp Dermatol; 2014 May; 23(5):352-3. PubMed ID: 24628992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1.
    Lang KS; Caroli CC; Muhm A; Wernet D; Moris A; Schittek B; Knauss-Scherwitz E; Stevanovic S; Rammensee HG; Garbe C
    J Invest Dermatol; 2001 Jun; 116(6):891-7. PubMed ID: 11407977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
    Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
    J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxychloroquine protects melanocytes from autoantibody-induced injury by reducing the binding of antigen-antibody complexes.
    Li DG; Hu WZ; Ma HJ; Liu W; Yang QQ; Zhao G
    Mol Med Rep; 2016 Aug; 14(2):1275-82. PubMed ID: 27277530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
    Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
    J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity.
    Norris DA; Kissinger RM; Naughton GM; Bystryn JC
    J Invest Dermatol; 1988 Jun; 90(6):783-9. PubMed ID: 3373009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.